Yellowstone Partners’s Novartis NVS Stock Holding History

Yellowstone Partners’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$542K	Sell	7,206 -381	-5%	-$28.7K	0.31%	78
2017 Q3	$584K	Buy	+7,587	New	+$573K	0.31%	85
2016 Q2	–	Sell	-10,340	Closed	-$671K	–	226
2016 Q1	$671K	Buy	10,340 +3,346	+48%	+$228K	0.29%	78
2015 Q4	$539K	Buy	6,994 +1,358	+24%	+$108K	0.24%	76
2015 Q3	$464K	Buy	5,636 +1,479	+36%	+$132K	0.22%	83
2015 Q2	$366K	Buy	4,157 +1,187	+40%	+$109K	0.17%	112
2015 Q1	$262K	Buy	2,970 +384	+15%	+$34.1K	0.13%	136
2014 Q4	$215K	Buy	+2,586	New	+$214K	0.12%	159

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Yellowstone Partners's NVS Position: Q4 2017 in Review

Yellowstone Partners reduced its Novartis (NVS) stake by 5% in Q4 2017, selling an estimated $28.7K and leaving 7,206 shares worth $542K. The position accounts for 0.31% of the portfolio, ranked #78.

Yellowstone Partners first reported a position in NVS in Q4 2014 and has held it in 8 quarters since. The position peaked at $671K in Q1 2016. 1,006 funds tracked by Wall St. Rank hold NVS as of Q4 2017.

Yellowstone Partners held 7,206 shares of Novartis worth $542K as of Q4 2017.
Yellowstone Partners sold 381 Novartis shares in Q4 2017, an estimated $28.7K.
Novartis made up 0.31% of Yellowstone Partners's portfolio in Q4 2017, its #78 holding.
Yellowstone Partners first reported a position in Novartis in Q4 2014 and has held it in 8 quarters since.
Yellowstone Partners's Novartis position peaked at $671K in Q1 2016.
1,006 funds tracked by Wall St. Rank held Novartis as of Q4 2017.

Based on Yellowstone Partners's 13F filing for Q4 2017, filed 24 Jan 2018.